Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and multiple ascending dose study of LY3322207 in healthy adults and adults with hypertension on ACE inhibitor/ARB therapy
NL-OMON45832Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of LY3322207 in chronic heart failure (CHF) (14 arms), sponsored by Eli Lilly and Company. Primary endpoints: Safety and tolerability after a single subcutaneous dose in healthy subjects, Safety and tolerability after multiple subcutaneous doses in healthy subjects and 1 more. Started Jul 2018; status: active, not recruiting.
02
Drugs
LY3322207
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON45832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45832.